AIO-Studien-gGmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
Phase 3
Terminated
- Conditions
- Renal Cell Cancer, RecurrentRenal Cell Carcinoma, Metastatic
- Interventions
- Behavioral: Concomitant coaching
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 121
- Registration Number
- NCT03013946
- Locations
- 🇩🇪
Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Bayern, Germany
🇩🇪Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
Phase 2
Terminated
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 49
- Registration Number
- NCT02959554
- Locations
- 🇩🇪
Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany
🇦🇹Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Carcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Biological: Nivolumab/Ipilimumab
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 200
- Registration Number
- NCT02917772
- Locations
- 🇫🇷
CHD Vendée, La Roche-Sur-Yon, France
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇨🇿Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia
Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients
Phase 4
Completed
- Conditions
- Adenocarcinoma Pancreas
- Interventions
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 32
- Registration Number
- NCT02812992
- Locations
- 🇩🇪
Universitätsklinikum Mannheim II. Medizinische Klinik, Mannheim, Germany
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer Stage IINon Small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer MetastaticSmall-cell Lung CancerNon-small Cell Lung Cancer Stage I
- Interventions
- Other: data collection
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 12400
- Registration Number
- NCT02622581
- Locations
- 🇩🇪
Pius-Hospital, Oldenburg, Germany
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
Phase 3
Terminated
- Conditions
- CancerVenous Thromboembolism
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 246
- Registration Number
- NCT02583191
- Locations
- 🇩🇪
Uniklinik, Aachen, Germany
Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)
Phase 2
Terminated
- Conditions
- Metastatic Squamous Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 41
- Registration Number
- NCT02564380
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
Phase 2
Completed
- Conditions
- Metastatic Pancreatic CancerAdenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 325
- Registration Number
- NCT02564146
- Locations
- 🇩🇪
Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany
Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction
Phase 1
Completed
- Conditions
- Adenocarcinoma,StomachAdenocarcinoma, Esophagogastric Junction
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 30
- Registration Number
- NCT02564367
- Locations
- 🇩🇪
Klinikum der Universität München, Campus Großhadern, München, Bayern, Germany
Maintaining ERBB Blockade in EGFR-mutated Lung Cancer
Phase 2
Terminated
- Conditions
- Non-small-cell Lung Cancer With Somatic EGFR Mutations
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 4
- Registration Number
- NCT02488694
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
© Copyright 2025. All Rights Reserved by MedPath